HIV Viral Load Testing in the South African Public Health Setting in the Context of Evolving ART Guidelines and Advances in Technology, 2013–2022

HIV viral load (VL) testing plays a key role in the clinical management of HIV as a marker of adherence and antiretroviral efficacy. To date, national and international antiretroviral treatment recommendations have evolved to endorse routine VL testing. South Africa (SA) has recommended routine VL testing since 2004. Progressively, the centralised HIV VL program managed by its National Health Laboratory Service (NHLS) has undergone expansive growth. Retrospective de-identified VL data from 2013 to 2022 were evaluated to review program performance. Test volumes increased from 1,961,720 performed in 2013 to 45,334,864 in 2022. The median total in-laboratory turnaround time (TAT) ranged from 94 h (2015) to 51 h (2022). Implementation of two new assays improved median TATs in all laboratories. Samples of VL greater than 1000 copies/mL declined steadily. Despite initial increases, samples of fewer than 50 copies/mL stagnated at about 70% from 2019 and declined to 68% in 2022. Some variations between assays were observed. Overall, the SA VL program is successful. The scale of the VL program, the largest of its kind in the world by some margin, provides lessons for future public health programs dependent on laboratories for patient outcome and program performance monitoring.

[1]  M. Siedner,et al.  Adherence, resistance, and viral suppression on dolutegravir in sub-Saharan Africa: implications for the TLD era , 2021, AIDS.

[2]  S. Rosen,et al.  Reduction in initiations of HIV treatment in South Africa during the COVID pandemic , 2021, BMC Health Services Research.

[3]  N. Ford,et al.  Comparative efficacy, tolerability and safety of dolutegravir and efavirenz 400mg among antiretroviral therapies for first-line HIV treatment: A systematic literature review and network meta-analysis , 2020, EClinicalMedicine.

[4]  J. Hodson,et al.  Correlation between Cepheid GeneXpert and Abbott M2000 assays for HIV viral load measurements , 2020, International journal of STD & AIDS.

[5]  C. Prégermain,et al.  Comparison of the Abbott Alinity m and m2000 assays for the quantification of HIV-1, HCV and HBV in clinical samples. , 2020, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[6]  Robert W Eisinger,et al.  HIV Viral Load and Transmissibility of HIV Infection: Undetectable Equals Untransmittable. , 2019, JAMA.

[7]  M. Fox,et al.  Changing the South African national antiretroviral therapy guidelines: The role of cost modelling , 2017, PloS one.

[8]  S. Lawn,et al.  Rates of Switching Antiretroviral Drugs in a Primary Care Service in South Africa before and after Introduction of Tenofovir , 2013, PloS one.

[9]  Bryan R Cobb,et al.  Evolution in the sensitivity of quantitative HIV-1 viral load tests. , 2011, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[10]  Wendy S Stevens,et al.  Challenges in implementing HIV load testing in South Africa. , 2010, The Journal of infectious diseases.

[11]  R. Pennell,et al.  HIV/AIDS , 2006 .

[12]  D. Chernoff The Significance of HIV Viral Load Assay Precision: A Review of the Package Insert Specifications of Two Commercial Kits , 2002, Journal of the International Association of Physicians in AIDS Care.

[13]  R. Dewar,et al.  Comparative Analysis of HIV-1 Viral Load Assays on Subtype Quantification: Bayer Versant HIV-1 RNA 3.0 Versus Roche Amplicor HIV-1 Monitor Version 1.5 , 2002 .

[14]  H Jacqmin-Gadda,et al.  Clinical progression of HIV-1 infection according to the viral response during the first year of antiretroviral treatment , 2000, AIDS.

[15]  Roger Detels,et al.  Plasma Viral Load and CD4+ Lymphocytes as Prognostic Markers of HIV-1 Infection , 1997, Annals of Internal Medicine.

[16]  F. Brun-Vézinet,et al.  Multicenter comparison of three commercial methods for quantification of human immunodeficiency virus type 1 RNA in plasma , 1996, Journal of clinical microbiology.

[17]  John W. Mellors,et al.  Prognosis in HIV-1 Infection Predicted by the Quantity of Virus in Plasma , 1996, Science.

[18]  Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV , 2020 .

[19]  James Curran,et al.  Scaling Up Antiretroviral Therapy in Resource-Limited Settings: Treatment Guidelines for a Public Health Approach , 2005 .

[20]  N. Michael,et al.  Joint United Nations Programme on HIV/AIDS. , 2004, Military medicine.

[21]  J. E. Kerrich Statistics in South Africa , 1968 .